Neoadjuvant treatment with T-DM1, lapatinib, and nab-paclitaxel demonstrated superior efficacy compared to standard treatment, particularly in the ER-positive cohort of early-stage HER2-positive breast cancer[49]. The gene discussed is ERBB2; the disease is breast cancer.